William F. Doyle

William F. Doyle (chief executive) discloses dealings in 4 companies, chiefly Novocure Ltd, Minerva Neurosciences, Inc. and Elanco Animal Health Inc. Between 5 October 2015 and 3 March 2026, the trades on record add up to 111 filings.

The open-market side counts 13 purchases for €651k alongside 51 sales for €64.8M. Sales outweigh purchases by €64.2M. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. Outside the open market, there are 18 share grants and 21 option exercises. So far in 2026, the count stands at no purchases and 2 sales.

In size, the median ticket on the buying side is €17k. Clusters matter here: 2 out of 13 purchases overlapped with buying by a colleague within 30 days. A cluster is several different insiders buying the same stock within a short window, a pattern studied more closely than a single purchase. After 13 purchases with a full 90-day history, the hit rate stands at 38% and the median 90-day move at -13.0%. This is a record of the past, not a forecast.

Most recently, on 5 March 2026, the filings show a share grant in Novocure Ltd. The last insider purchase was made public on 23 May 2024, 899 days ago. Filings reach the SEC (Form 4) feed a median of 2 days after the trade. The legal deadline for a Form 4 is two business days after the transaction. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.